Efficacy and safety of cord blood-derived cytokine-induced killer cells in treatment of patients with malignancies

Cytotherapy

Volumn 17, Issue 8, 2015, Pages 1130-1138

  Zhang, Zhen ^a   Wang, Liping ^a   Luo, Zhenzhen ^a   Zhao, Xuan ^a   Huang, Jianmin ^a   Li, Hong ^a   Yang, Shuangning ^a   Zhao, Xianlan ^a   Zhang, Lei ^a   Li, Liuxia ^a   Wang, Feng ^a   Huang, Lan ^a   Zhang, Yi ^a,b,c  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

^c Biomass Key Laboratory of Henan Province   (China)

Author keywords

Cord blood; Cytokine induced killer cells; Efficacy; Malignancies; Safety

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; LEUKOCYTE ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ADULT; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); COLON CANCER; CYTOKINE INDUCED KILLER CELL; DIARRHEA; DIZZINESS; ESOPHAGUS CANCER; FEASIBILITY STUDY; FEMALE; FEVER; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; LUNG CANCER; LYMPHOCYTE COUNT; MALE; MALIGNANT NEOPLASTIC DISEASE; MIDDLE AGED; NAUSEA; NEUROTOXICITY; OVARY CANCER; PATIENT SAFETY; PRIORITY JOURNAL; RECTUM CANCER; RETROSPECTIVE STUDY; SHIVERING; STOMACH CANCER; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; AGED; BIOLOGICAL THERAPY; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; CYTOLOGY; FETUS BLOOD; IMMUNOLOGY; METABOLISM; NEOPLASMS; PROCEDURES; TRANSPLANTATION;

ADULT; AGED; ANTIGENS, CD; CD4-POSITIVE T-LYMPHOCYTES; CELL- AND TISSUE-BASED THERAPY; CYTOKINE-INDUCED KILLER CELLS; FEMALE; FETAL BLOOD; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 84937637214     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2015.04.002     Document Type: Article

References (44)

1. Restifo N.P., Dudley M.E., Rosenberg S.A. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012, 12:269-281.
2. Yee C. Adoptive T-cell therapy for cancer: boutique therapy or treatment modality?. Clin Cancer Res 2013, 19:4550-4552.
3. Zhao H., Wang R., Tao Z., Yan F., Gao L., Liu X., et al. Activation of T-LAK-cell-originated protein kinase-mediated antioxidation protects against focal cerebral ischemia-reperfusion injury. FEBS J 2014, 281:4411-4420.
4. Semenzato G. Lymphokine activated killer cells: a new approach to immunotherapy of cancer. Leukemia 1990, 4:71-80.
5. West E.J., Scott K.J., Jennings V.A., Melcher A.A. Immune activation by combination human lymphokine-activated killer and dendritic cell therapy. Br J Cancer 2011, 105:787-795.
6. Robbins P.F., Morgan R.A., Feldman S.A., Yang J.C., Sherry R.M., Dudley M.E., et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011, 29:917-924.
7. Dudley M.E., Gross C.A., Somerville R.P., Hong Y., Schaub N.P., Rosati S.F., et al. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J Clin Oncol 2013, 31:2152-2159.
8. Thanendrarajan S., Kim Y., Schmidt-Wolf I. New adoptive immunotherapy strategies for solid tumours with CIK cells. Expert Opin Biol Ther 2012, 12:565-572.
9. Liu L., Zhang W., Qi X., Li H., Yu J., Wei S., et al. Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res 2012, 18:1751-1759.
10. Wei C., Wang W., Pang W., Meng M., Jiang L., Xue S., et al. The CIK cells stimulated with combination of IL-2 and IL-15 provide an improved cytotoxic capacity against human lung adenocarcinoma. Tumour Biol 2014, 35:1997-2007.
11. Wu C., Jiang J., Shi L., Xu N. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res 2008, 28:3997-4002.
12. Mesiano G., Todorovic M., Gammaitoni L., Leuci V., Giraudo Diego L., Carnevale-Schianca F., et al. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert Opin Biol Ther 2012, 12:673-684.
13. Helms M.W., Prescher J.A., Cao Y.A., Schaffert S., Contag C.H. IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy. Cancer Immunol Immunother 2010, 59:1325-1334.
14. Li Y., Schmidt-Wolf I.G., Wu Y.F., Huang S.L., Wei J., Fang J., et al. Optimized protocols for generation of cord blood-derived cytokine-induced killer/natural killer cells. Anticancer Res 2010, 30:3493-3499.
15. Zhang Q., Wang L., Luo C., Shi Z., Cheng X., Zhang Z., et al. Phenotypic and functional characterization of cytokine-induced killer cells derived from preterm and term infant cord blood. Oncol Rep 2014, 32:2244-2252.
16. Durrieu L., Lemieux W., Dieng M.M., Fontaine F., Duval M., Le Deist F., et al. Implication of different effector mechanisms by cord blood-derived and peripheral blood-derived cytokine-induced killer cells to kill precursor B acute lymphoblastic leukemia cell lines. Cytotherapy 2014, 16:845-856.
17. Zhang Z., Zhao X., Zhang T., Wang L., Yang L., Huang L., et al. Phenotypic characterization and anti-tumor effects of cytokine-induced killer cells derived from cord blood. Cytotherapy 2015, 17:86-97.
18. Durrieu L., Gregoire-Gauthier J., Dieng M.M., Fontaine F., le Deist F., Haddad E. Human interferon-alpha increases the cytotoxic effect of CD56(+) cord blood-derived cytokine-induced killer cells on human B-acute lymphoblastic leukemia cell lines. Cytotherapy 2012, 14:1245-1257.
19. Wongkajornsilp A., Wamanuttajinda V., Kasetsinsombat K., Duangsa-ard S., Sa-ngiamsuntorn K., Hongeng S., et al. Sunitinib indirectly enhanced anti-tumor cytotoxicity of cytokine-induced killer cells and CD3(+)CD56(+) subset through the co-culturing dendritic cells. PLoS One 2013, 8:e78980.
20. Zhang Z., Wang L.P., Zhao X.L., Wang F., Huang L., Wang M., et al. Pseudomonas aeruginosa injection enhanced antitumor cytotoxicity of cytokine-induced killer cells derived from cord blood. Biomed Pharmacother 2014, 68:1057-1063.
21. Niu Q., Wang W., Li Y., Qin S., Wang Y., Wan G., et al. Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies. Int Immunopharmacol 2011, 11:449-456.
22. Shi S.B., Tang X.Y., Tian J., Chang C.X., Li P., Qi J.L. Efficacy of erlotinib plus dendritic cells and cytokine-induced killer cells in maintenance therapy of advanced non-small cell lung cancer. J Immunother 2014, 37:250-255.
23. Tang Y., Li X., Wang M., Zou Q., Zhao S., Sun B., et al. Increased numbers of NK cells, NKT-like cells, and NK inhibitory receptors in peripheral blood of patients with chronic obstructive pulmonary disease. Clin Dev Immunol 2013, 2013:721782.
24. Tarokhian B., Sherkat R., Nasr Esfahani M.H., Adib M., Kiani Esfahani A., Ataei B. CD107a Expression and IFN-gamma Production as Markers for Evaluation of Cytotoxic CD3+ CD8+ T Cell Response to CMV Antigen in Women with Recurrent Spontaneous Abortion. Int J Fertil Steril 2014, 7:323-330.
25. Zhu Y., Zhang H., Li Y., Bai J., Liu L., Liu Y., et al. Efficacy of postoperative adjuvant transfusion of cytokine-induced killer cells combined with chemotherapy in patients with colorectal cancer. Cancer Immunol Immunother 2013, 62:1629-1635.
26. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
27. Gao D., Li C., Xie X., Zhao P., Wei X., Sun W., et al. Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients. PLoS One 2014, 9:e93886.
28. Grupp S.A., Prak E.L., Boyer J., McDonald K.R., Shusterman S., Thompson E., et al. Adoptive transfer of autologous T cells improves T-cell repertoire diversity and long-term B-cell function in pediatric patients with neuroblastoma. Clin Cancer Res 2012, 18:6732-6741.
29. Klebanoff C.A., Gattinoni L., Restifo N.P. Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?. J Immunother 2012, 35:651-660.
30. Zhong R., Han B., Zhong H. A prospective study of the efficacy of a combination of autologous dendritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients. Tumour Biol 2014, 35:987-994.
31. Wang D., Li J., Liu J.Y., Li F., Wang L.P., Huang L., et al. Modification of chemokine receptor expression to enhance levels of trafficking receptors on autologous cytokine-induced killer cells derived from patients with colorectal cancer. Biomed Pharmacother 2014, 68:551-556.
32. Liu J., Li H., Cao S., Zhang X., Yu J., Qi J., et al. Maintenance therapy with autologous cytokine-induced killer cells in patients with advanced epithelial ovarian cancer after first-line treatment. J Immunother 2014, 37:115-122.
33. Pan K., Guan X.X., Li Y.Q., Zhao J.J., Li J.J., Qiu H.J., et al. Clinical activity of adjuvant cytokine-induced killer cell immunotherapy in patients with post-mastectomy triple-negative breast cancer. Clin Cancer Res 2014, 20:3003-3011.
34. Cui J., Wang N., Zhao H., Jin H., Wang G., Niu C., et al. Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma. Int J Cancer 2014, 134:342-351.
35. Durrieu L., Dieng M.M., Le Deist F., Haddad E. Cord blood-derived and peripheral blood-derived cytokine-induced killer cells are sensitive to Fas-mediated apoptosis. Biol Blood Marrow Transplant 2013, 19:1407-1411.
36. Rossjohn J., Pellicci D.G., Patel O., Gapin L., Godfrey D.I. Recognition of CD1d-restricted antigens by natural killer T cells. Nat Rev Immunol 2012, 12:845-857.
37. Ma Y., Xu Y.C., Tang L., Zhang Z., Wang J., Wang H.X. Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety. Exp Hematol Oncol 2012, 1:11.
38. Zhang J., Zhu L., Wei J., Liu L., Yin Y., Gu Y., et al. The effects of cytokine-induced killer cells for the treatment of patients with solid tumors: a clinical retrospective study. J Cancer Res Clin Oncol 2012, 138:1057-1062.
39. Saga K., Tamai K., Yamazaki T., Kaneda Y. Systemic administration of a novel immune-stimulatory pseudovirion suppresses lung metastatic melanoma by regionally enhancing IFN-gamma production. Clin Cancer Res 2013, 19:668-679.
40. Alter G., Malenfant J.M., Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 2004, 294:15-22.
41. Ma Y., Zhang Z., Tang L., Xu Y.C., Xie Z.M., Gu X.F., et al. Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis. Cytotherapy 2012, 14:483-493.
42. Sun Z., Shi L., Zhang H., Shao Y., Wang Y., Lin Y., et al. Immune modulation and safety profile of adoptive immunotherapy using expanded autologous activated lymphocytes against advanced cancer. Clin Immunol 2011, 138:23-32.
43. Li X.D., Ji M., Zheng X., Ning Z.H., Wu J., Lu B., et al. Evaluation of tumor response to cytokine-induced killer cells therapy in malignant solid tumors. J Transl Med 2014, 12:215.
44. Bemelmans R.H., van Toorn D.W., van Leeuwen L., Schaar C.G. Long-term complete remission in IgD-myeloma. Eur J Haematol 2006, 76:339-341.